nabiximols 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
cannabinoid receptors agonists	4793	56575-23-6

Description:

Molecule	Description
Synonyms: cannabinoids GW-1000 nabiximols nabidiolex sativex tetranabinex	Compounds having the cannabinoid structure. They were originally extracted from Cannabis sativa L. The most pharmacologically active constituents are TETRAHYDROCANNABINOL; CANNABINOL; and CANNABIDIOL. Molecular weight: 628.94 Formula: C42H60O4 CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: 29.46 ALOGS: ROTB: None

Molecule

Description

Synonyms:

cannabinoids
GW-1000
nabiximols
nabidiolex
sativex
tetranabinex

Compounds having the cannabinoid structure. They were originally extracted from Cannabis sativa L. The most pharmacologically active constituents are TETRAHYDROCANNABINOL; CANNABINOL; and CANNABIDIOL.

Molecular weight: 628.94
Formula: C42H60O4
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA: 29.46
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Multiple sclerosis relapse	129.29	30.53	45	1229	48433	63439315
COVID-19	95.45	30.53	46	1228	113057	63374691
Muscle spasticity	38.55	30.53	15	1259	21779	63465969
Lymphopenia	33.78	30.53	13	1261	18314	63469434
SARS-CoV-2 antibody test negative	30.93	30.53	5	1269	184	63487564

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
COVID-19	58.42	43.36	22	252	77528	34879129

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Multiple sclerosis relapse	166.14	31.97	53	1451	46480	79696404
COVID-19	146.06	31.97	67	1437	157607	79585277
SARS-CoV-2 antibody test negative	44.49	31.97	7	1497	231	79742653
Muscle spasticity	43.31	31.97	16	1488	21459	79721425
Urinary tract infection	37.36	31.97	35	1469	274477	79468407

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N02BG10	NERVOUS SYSTEM ANALGESICS OTHER ANALGESICS AND ANTIPYRETICS Other analgesics and antipyretics
MeSH PA	D000700	Analgesics
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D018689	Sensory System Agents
CHEBI has role	CHEBI:67072	cannabinoid receptor agonists

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Muscle Spasticity due to Multiple Sclerosis	indication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
K4H93P747O	UNII
D09317	KEGG_DRUG
C2347556	UMLSCUI
CHEBI:67194	CHEBI
CHEMBL3833333	ChEMBL_ID
44148067	PUBCHEM_CID
DB14011	DRUGBANK_ID
C587251	MESH_SUPPLEMENTAL_RECORD_UI
421921003	SNOMEDCT_US
766895006	SNOMEDCT_US
D002186	MESH_DESCRIPTOR_UI

Pharmaceutical products:

None